Ekman S - Search Results

1

Dose escalation to 84 Gy with concurrent chemotherapy in stage III NSCLC appears excessively toxic: Results from a prematurely terminated randomized phase II trial.

Hallqvist A, Bergström S, Björkestrand H, Svärd AM, Ekman S, Lundin E, Holmberg E, Johansson M, Friesland S, Nyman J. Hallqvist A, et al. Among authors: ekman s. Lung Cancer. 2018 Aug;122:180-186. doi: 10.1016/j.lungcan.2018.06.020. Epub 2018 Jun 18. Lung Cancer. 2018. PMID: 30032828 Clinical Trial.

2

Role of circulating cytokeratin fragments and angiogenic factors in NSCLC patients stage IIIa-IIIb receiving curatively intended treatment.

Eriksson P, Brattström D, Hesselius P, Larsson A, Bergström S, Ekman S, Goike H, Wagenius G, Brodin O, Bergqvist M. Eriksson P, et al. Among authors: ekman s. Neoplasma. 2006;53(4):285-90. Neoplasma. 2006. PMID: 16830054

3

Clinical value of using serological cytokeratins as therapeutic markers in thoracic malignancies.

Ekman S, Eriksson P, Bergström S, Johansson P, Goike H, Gullbo J, Henriksson R, Larsson A, Bergqvist M. Ekman S, et al. Anticancer Res. 2007 Sep-Oct;27(5B):3545-53. Anticancer Res. 2007. PMID: 17972516 Free article. Review.

4

Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.

Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J, Ekman S. Wu X, et al. Among authors: ekman s. Br J Cancer. 2009 Jan 27;100(2):334-43. doi: 10.1038/sj.bjc.6604855. Epub 2009 Jan 13. Br J Cancer. 2009. PMID: 19142186 Free PMC article.

5

Impact of age at diagnosis on prognosis and treatment in laryngeal cancer.

Reizenstein JA, Bergström SN, Holmberg L, Linder A, Ekman S, Blomquist E, Lödén B, Holmqvist M, Hellström K, Nilsson CO, Brattström D, Bergqvist M. Reizenstein JA, et al. Among authors: ekman s. Head Neck. 2010 Aug;32(8):1062-8. doi: 10.1002/hed.21292. Head Neck. 2010. PMID: 19953624

6

Hsp90 as a therapeutic target in patients with oesophageal carcinoma.

Ekman S, Bergqvist M, Tell R, Bergström S, Lennartsson J. Ekman S, et al. Expert Opin Ther Targets. 2010 Mar;14(3):317-28. doi: 10.1517/14728221003621278. Expert Opin Ther Targets. 2010. PMID: 20148718 Review.

7

Molecular profiling using tissue microarrays as a tool to identify predictive biomarkers in laryngeal cancer treated with radiotherapy.

Holgersson G, Ekman S, Reizenstein J, Bergqvist M, Pontén F, Uhlén M, Magnusson K, Jonnalagadda P, Asplund A, Strömberg S, Linder A, Blomquist E, Liljeholm M, Lödén B, Hellström K, Bergström S. Holgersson G, et al. Among authors: ekman s. Cancer Genomics Proteomics. 2010 Jan-Feb;7(1):1-7. Cancer Genomics Proteomics. 2010. PMID: 20181625

8

Mast cells in squamous cell esophageal carcinoma and clinical parameters.

Tinge B, Molin D, Bergqvist M, Ekman S, Bergström S. Tinge B, et al. Among authors: ekman s. Cancer Genomics Proteomics. 2010 Jan-Feb;7(1):25-9. Cancer Genomics Proteomics. 2010. PMID: 20181628

9

Dual-headed coincidence PET vs. dedicated PET/CT in the evaluation of thoracic malignancies.

Bergström S, Holgersson G, Bergqvist JE, Bergqvist M, Ekman S, Stenström M. Bergström S, et al. Among authors: ekman s. In Vivo. 2010 Mar-Apr;24(2):235-8. In Vivo. 2010. PMID: 20364002

10

Clinical Phase I study with an Insulin-like Growth Factor-1 receptor inhibitor: experiences in patients with squamous non-small cell lung carcinoma.

Ekman S, Frödin JE, Harmenberg J, Bergman A, Hedlund A, Dahg P, Alvfors C, Ståhl B, Bergström S, Bergqvist M. Ekman S, et al. Acta Oncol. 2011 Apr;50(3):441-7. doi: 10.3109/0284186X.2010.499370. Epub 2010 Aug 11. Acta Oncol. 2011. PMID: 20698809 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

333 results

Search Page